Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study

Bruno Daniele, Adina Croitoru, Christos Papandreou, Jean Pierre Bronowicki, Philippe Mathurin, Fatima Serejo, Per Stål, Juan Turnes, Vlad Ratziu, G. Bodoky

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

SUMMARY Aims: To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation. Patients & methods: Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up. Results: Of 1113 evaluable patients, 82% started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88%). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day. Conclusion: Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.

Original languageEnglish
Pages (from-to)2553-2562
Number of pages10
JournalFuture Oncology
Volume11
Issue number18
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Survival
Disease Progression
sorafenib
Therapeutics
History
Demography
Safety
Incidence

Keywords

  • dosing
  • GIDEON
  • safety
  • sorafenib
  • unresectable hepatocellular carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Daniele, B., Croitoru, A., Papandreou, C., Bronowicki, J. P., Mathurin, P., Serejo, F., ... Bodoky, G. (2015). Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncology, 11(18), 2553-2562. https://doi.org/10.2217/fon.15.163

Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. / Daniele, Bruno; Croitoru, Adina; Papandreou, Christos; Bronowicki, Jean Pierre; Mathurin, Philippe; Serejo, Fatima; Stål, Per; Turnes, Juan; Ratziu, Vlad; Bodoky, G.

In: Future Oncology, Vol. 11, No. 18, 01.09.2015, p. 2553-2562.

Research output: Contribution to journalArticle

Daniele, B, Croitoru, A, Papandreou, C, Bronowicki, JP, Mathurin, P, Serejo, F, Stål, P, Turnes, J, Ratziu, V & Bodoky, G 2015, 'Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study', Future Oncology, vol. 11, no. 18, pp. 2553-2562. https://doi.org/10.2217/fon.15.163
Daniele B, Croitoru A, Papandreou C, Bronowicki JP, Mathurin P, Serejo F et al. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncology. 2015 Sep 1;11(18):2553-2562. https://doi.org/10.2217/fon.15.163
Daniele, Bruno ; Croitoru, Adina ; Papandreou, Christos ; Bronowicki, Jean Pierre ; Mathurin, Philippe ; Serejo, Fatima ; Stål, Per ; Turnes, Juan ; Ratziu, Vlad ; Bodoky, G. / Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. In: Future Oncology. 2015 ; Vol. 11, No. 18. pp. 2553-2562.
@article{d0011ffefdcc41f5b1752998aa43658f,
title = "Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study",
abstract = "SUMMARY Aims: To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation. Patients & methods: Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up. Results: Of 1113 evaluable patients, 82{\%} started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88{\%}). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day. Conclusion: Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.",
keywords = "dosing, GIDEON, safety, sorafenib, unresectable hepatocellular carcinoma",
author = "Bruno Daniele and Adina Croitoru and Christos Papandreou and Bronowicki, {Jean Pierre} and Philippe Mathurin and Fatima Serejo and Per St{\aa}l and Juan Turnes and Vlad Ratziu and G. Bodoky",
year = "2015",
month = "9",
day = "1",
doi = "10.2217/fon.15.163",
language = "English",
volume = "11",
pages = "2553--2562",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "18",

}

TY - JOUR

T1 - Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study

AU - Daniele, Bruno

AU - Croitoru, Adina

AU - Papandreou, Christos

AU - Bronowicki, Jean Pierre

AU - Mathurin, Philippe

AU - Serejo, Fatima

AU - Stål, Per

AU - Turnes, Juan

AU - Ratziu, Vlad

AU - Bodoky, G.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - SUMMARY Aims: To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation. Patients & methods: Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up. Results: Of 1113 evaluable patients, 82% started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88%). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day. Conclusion: Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.

AB - SUMMARY Aims: To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation. Patients & methods: Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up. Results: Of 1113 evaluable patients, 82% started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88%). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day. Conclusion: Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.

KW - dosing

KW - GIDEON

KW - safety

KW - sorafenib

KW - unresectable hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84942938260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942938260&partnerID=8YFLogxK

U2 - 10.2217/fon.15.163

DO - 10.2217/fon.15.163

M3 - Article

C2 - 26158398

AN - SCOPUS:84942938260

VL - 11

SP - 2553

EP - 2562

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 18

ER -